{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:23:34Z","timestamp":1789190614086,"version":"build-2803163510"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer antigen 125 (CA125) is the best known single tumor marker for ovarian cancer (OC). We investigated whether the additional information of the human epididymis protein 4 (HE4) improves diagnostic accuracy.<\/jats:p><jats:p>We retrospectively analyzed preoperative sera of 109 healthy women, 285 patients with benign ovarian masses (cystadenoma: n=78, leimyoma: n=66, endometriosis: n=52, functional ovarian cysts: n=79, other: n=10), 16 low malignant potential (LMP) ovarian tumors and 125 OC (stage I: 22, II: 15, III: 78, IV: 10). CA125 was analyzed using the ARCHITECT system, HE4 using the ARCHITECT(a) system and EIA(e) technology additionally.<\/jats:p><jats:p>The lowest concentrations of CA125 and HE4 were observed in healthy individuals, followed by patients with benign adnexal masses and patients with LMP tumors and OC. The area under the curve (AUC) for the differential diagnosis of adnexal masses of CA125 alone was not significantly different to HE4 alone in premenopausal (CA125: 86.7, HE4(a): 82.6, HE4(e): 81.6% p&gt;0.05) but significantly different in postmenopausal [CA125: 93.4 vs. HE4(a): 88.3 p=0.023 and vs. HE4(e): 87.8% p=0.012] patients. For stage I OC, HE4 as a single marker was superior to CA125, which was the best single marker in stage II-IV. The combination of CA125 and HE4 using risk of malignancy algorithm (ROMA) gained the highest sensitivity at 95% specificity for the differential diagnosis of adnexal masses [CA125: 70.9, HE4(a): 67.4, HE4(e): 66.0, ROMA(a): 76.6 and ROMA(e): 74.5%], especially in stage I OC [CA125: 27.3, HE4(a): 40.9, HE4(e): 40.9, ROMA(a): 45.5 and ROMA(e): 45.5%].<\/jats:p><jats:p>CA125 is still the best single marker in the diagnosis of OC. HE4 alone and even more the combined analysis of CA125 and HE4 using ROMA improve the diagnostic accuracy of adnexal masses, especially in early OC.<\/jats:p>","DOI":"10.1515\/cclm.2011.709","type":"journal-article","created":{"date-parts":[[2011,9,17]],"date-time":"2011-09-17T03:58:35Z","timestamp":1316231915000},"source":"Crossref","is-referenced-by-count":46,"title":["The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses"],"prefix":"10.1515","volume":"49","author":[{"given":"Miriam","family":"Lenhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hertlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Kirschenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Krocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","article-title":"A method of comparing the areas under receiver operating characteristic curves derived from the same cases","volume":"148","author":"Hanley","year":"1983","journal-title":"Radiology"},{"key":"ref81","first-page":"000","article-title":"Coo - per Ovarian cancer screening with annual transvaginal sonography : findings of women screened","volume":"25","author":"van Nagell","year":"2007","journal-title":"Cancer"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0028-2243(93)90135-Y","article-title":"von Mensdorff CA in gynecological pathology a review","volume":"49","author":"Kenemans","year":"1993","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay util - izing HE and CA for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ygyno.2009.11.014","article-title":"van den Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses","volume":"116","author":"Akker","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/AOG.0b013e3181d44053","article-title":"Predicting risk of malignancy in adnexal masses","volume":"115","author":"McDonald","year":"2010","journal-title":"Obstet Gynecol"},{"key":"ref201","first-page":"1","article-title":"Kader Ali Risk Malignancy Index in patients with abnormal pelvic mass : Comparing RMI in an Aus - tralian population","volume":"50","author":"Mohan","year":"2010","journal-title":"J Obstet Gynaecol"},{"key":"ref111","first-page":"322","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer Results of two prospective random - ized trials","author":"Young","year":"1990","journal-title":"Engl J Med"},{"key":"ref221","first-page":"865","article-title":"The risk of malignancy index in diagnosis of ovarian malignancy","volume":"10","author":"Moolthiya","year":"2009","journal-title":"Cancer Prev"},{"key":"ref51","first-page":"142","article-title":"da Accuracy of CA in the diagnosis of ovarian tumors : a quantitative systematic review","author":"Medeiros","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1067\/mob.2000.105940","article-title":"CA measurement and ultrasonography in borderline tumors of the ovary","volume":"183","author":"Gotlieb","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"ref131","first-page":"2088","article-title":"Pro - : Diagnostic accuracy of HE testing systems in ovarian cancer Article in press - uncorrected proof teins with whey - acidic - protein motifs and cancer","volume":"7","author":"Bouchard","year":"2006","journal-title":"Lancet Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"von Human epididymis protein ) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1515\/CCLM.2009.134","article-title":"Predictive value of CA and CA - in ovarian borderline tumors","volume":"47","author":"Lenhard","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE in patients with endometrioid adenocarcinoma of the uterus","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE and CA as a diagnostic test in ovarian cancer : prospective validation of the Risk of Ovarian Malig - nancy Algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br J Cancer"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref21","first-page":"709","article-title":"A new biometrical procedure for testing the equality of measurements from two different analytical methods Application of linear regression procedures for meth - od comparison studies in clinical chemistry","volume":"21","author":"Passing","year":"1983","journal-title":"Clin Chem Clin Biochem"},{"key":"ref01","first-page":"1","article-title":"e The utility of serum human epididymis protein ) in patients with a pelvic mass","volume":"4","author":"Montagnana","year":"1989","journal-title":"Hum Reprod J Clin Lab Anal"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.2910420507","article-title":"Elevated serum CA levels prior to diagnosis of ovarian neoplasia : relevance for early detection of ovarian cancer","volume":"42","author":"Zurawski","year":"1988","journal-title":"Int J Cancer"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2011.49.issue-12\/cclm.2011.709\/cclm.2011.709.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2011.709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:04:20Z","timestamp":1619046260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2011.709\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":20,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1515\/cclm.2011.709","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,1]]}}}